BR0116001A - Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda - Google Patents

Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda

Info

Publication number
BR0116001A
BR0116001A BR0116001-0A BR0116001A BR0116001A BR 0116001 A BR0116001 A BR 0116001A BR 0116001 A BR0116001 A BR 0116001A BR 0116001 A BR0116001 A BR 0116001A
Authority
BR
Brazil
Prior art keywords
methods
receptor antagonists
nmda receptor
neuropsychiatric disorders
modulating
Prior art date
Application number
BR0116001-0A
Other languages
English (en)
Inventor
Stuart M D Lipton
Original Assignee
Neuromolecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuromolecular Inc filed Critical Neuromolecular Inc
Publication of BR0116001A publication Critical patent/BR0116001A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODOS PARA TRATAR DISTúRBIOS NEUROPSIQUIáTRICOS COM ANTAGONISTAS RECEPTORES NMDA". A presente invenção refere-se a composições e processos para tratamento de um paciente humano atacado por uma desordem neuro - psiquiátrica. Especificamente, a invenção provê composições e processos de modulação ou antagonização de atividade de receptores NMDA neuronais, onde tal atividade antagonística é capaz de modular a resposta excitante dos neurónios induzida por glutamato, pelo que inibindo um efeito excitotóxico, promovendo um efeito neurotrófico, e pelo que provendo um efeito terapêutico que trata a desordem neuropsiquiátrica.
BR0116001-0A 2000-12-07 2001-12-07 Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda BR0116001A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25400700P 2000-12-07 2000-12-07
PCT/US2001/048516 WO2002045710A1 (en) 2000-12-07 2001-12-07 Methods for treating neuropsychiatric disorders with nmda receptor antagonists

Publications (1)

Publication Number Publication Date
BR0116001A true BR0116001A (pt) 2004-07-06

Family

ID=22962564

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116001-0A BR0116001A (pt) 2000-12-07 2001-12-07 Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda

Country Status (8)

Country Link
EP (1) EP1351670A4 (pt)
JP (1) JP2004515477A (pt)
CN (1) CN1486180A (pt)
AU (1) AU2002229056A1 (pt)
BR (1) BR0116001A (pt)
CA (1) CA2436311A1 (pt)
MX (1) MXPA03005130A (pt)
WO (1) WO2002045710A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US8500795B2 (en) 1999-08-09 2013-08-06 Cardiokinetix, Inc. Retrievable devices for improving cardiac function
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US8377114B2 (en) 1999-08-09 2013-02-19 Cardiokinetix, Inc. Sealing and filling ventricular partitioning devices to improve cardiac function
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
TW200403066A (en) * 2002-04-30 2004-03-01 Novartis Ag New uses of substituted aminoalkanephosphonic acids
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
MXPA06014587A (es) * 2004-06-17 2007-04-27 Forest Laboratories Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.
AU2006259619A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
WO2007130724A2 (en) 2006-02-06 2007-11-15 Northwind Ventures Systems and methods for volume reduction
CN103211824B (zh) * 2006-04-13 2017-04-19 纽若泰克制药株式会社 用于治疗或预防退行性和炎症性疾病的药物组合物
IT1396556B1 (it) 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
CN102070463A (zh) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用
EP2493417B1 (en) 2009-10-26 2017-06-21 Cardiokinetix, Inc. Ventricular volume reduction
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
JP5562716B2 (ja) 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US9868975B2 (en) * 2014-04-30 2018-01-16 Yufeng Jane Tseng Use of known compounds as D-amino acid oxidase inhibitors
CN105294450B (zh) * 2014-05-29 2024-05-17 广州喜鹊医药有限公司 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
US10751183B2 (en) 2014-09-28 2020-08-25 Edwards Lifesciences Corporation Apparatuses for treating cardiac dysfunction
KR20240068766A (ko) * 2015-05-22 2024-05-17 비스타젠 쎄라퓨틱스, 인크. L-４-클로로키누레닌의 치료적 용도
US10898330B2 (en) 2017-03-28 2021-01-26 Edwards Lifesciences Corporation Positioning, deploying, and retrieving implantable devices
WO2019028025A1 (en) * 2017-08-01 2019-02-07 Lipton Stuart A METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS
US11447442B2 (en) 2017-11-22 2022-09-20 Panorama Research, Inc. Aminoadamantyl nitrate compounds and their use to treat CNS disorders
CN109206317B (zh) * 2018-09-12 2021-07-09 青岛海蓝医药有限公司 一种金刚烷胺类硝酸酯衍生物的制备工艺
CN110938006A (zh) * 2019-12-04 2020-03-31 重庆植恩药业有限公司 盐酸美金刚杂质c的制备方法
CN114544826B (zh) * 2020-11-24 2023-12-08 重庆医科大学 检测血浆中组氨酸的试剂在制备抑郁症检测试剂盒中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584718A (ja) * 1981-06-30 1983-01-11 Nippon Chibagaigii Kk 新規適応症に用うる医薬製剤
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents

Also Published As

Publication number Publication date
WO2002045710A9 (en) 2003-04-24
CN1486180A (zh) 2004-03-31
EP1351670A1 (en) 2003-10-15
MXPA03005130A (es) 2004-12-06
WO2002045710A1 (en) 2002-06-13
CA2436311A1 (en) 2002-06-13
AU2002229056A1 (en) 2002-06-18
EP1351670A4 (en) 2004-07-07
JP2004515477A (ja) 2004-05-27

Similar Documents

Publication Publication Date Title
BR0116001A (pt) Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda
BR9602485A (pt) Método para o tratamento da doença de Parkinson composição farmacêutica primeira composição farmacêutica e método para a obtenção de efeito antiParkinson
BR0007556A (pt) Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos
CY1110512T1 (el) Πολυκυκλοαλκυλοπουρινες ως ανταγωνιστες υποδοχεων αδενοσινης
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
ATE302194T1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
PA8493701A1 (es) Compuestos para tratar la obesidad
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
NO990912D0 (no) Terapeutiske kombinasjoner av PAR-antagonister og RXR-antagonister og deres anvendelse
BR0313624A (pt) Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória
BR9812660A (pt) Composições e métodos para tratar distúrbios respiratórios
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
PT1562954E (pt) Antagonistas de ccr1 para o tratamento da doenca desmielinzante inflamatoria i.a.
PL1617836T3 (pl) Kompozycja odżywcza lub lecznicza zawierająca oleuropeinę lub jedną z jej pochodnych
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
HUP0203371A2 (hu) Adenozinreceptor antagonisták, eljárás ezek előállítására és alkalmazásuk
BR0008603A (pt) Método para tratamento de copd
MX9305933A (es) Metodo para antagonizar al 1,4,5-trifosfato de inositol.
BR9814867A (pt) Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
EP1852113A3 (en) Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
WO2003103675A3 (en) COMBINATION THERAPIES FOR PURINOCEPTOR RELATED DISORDERS

Legal Events

Date Code Title Description
B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 VIII E 11 DA LPI

B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.